FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321172020> ?p ?o ?g. }

• W2321172020 endingPage "641" @default.
• W2321172020 startingPage "641" @default.
• W2321172020 abstract "Background: To reduce side effects such as hyperlipidemia, pain on injection, and bacterial growth of the present formation of propofol, many attempts to change its formulation have been tried. We have developed a newly formulated poloxamer-solutol propofol, which is includes soy bean oil and egg phosphatide as sufactants. The aim of this study was to evaluate the poloxamer-solutol propofol regarding its pharmacokinetic and pharmacodynamic characteristics and bacterial growth compared to original propofol. Methods: Thirty Beagle dogs weighing around 10-15 kg were randomly assigned to one of two groups. Group 1 received Diprivan propofol 1% (AstraZeneca Co. UK), Group 2 received poloxamer-solutol formulated propofol by continuous intravenous infusion at 35 mg/kg/h for 3 hours. Three, 6, 9 and 12 hours after the discontinuation of the propofol infusion, venous samples from the anterior tibial vein were analysed for liver and renal function test. Also, blood lipid levels were checked after 3 hours of infusion and blood propofol concentrations were checked every hour during infusion. Eye opening time and orientation time, represented by walking on four legs, were evaluated. Also, broth cultures (100) of four standard preservative efficacy test organisms (Staphylococcus Aureus, Pseudomonas Aeruginosa, Escherichia Coli, Candida Albicans) were added to 9.9 ml of four test formulations at approximately 200 colony forming units/ml. The subjected formulations were; original propofol (AstraZeneca Co, 1% solution, UK), EDTA added propofol (0.0055% EDTA added propofol), Poloxamer-Solutol formulated propofol (poloxamer 188/407 and solutol mixture), and normal saline. The test formulations were incubated at 25 and 32.5 (Tryptic soy agar medium for bacteria and Sabrouraud dextrose agar medium for fungus) and tested for viable counts after 24 and 48 hours. Results: Poloxamer-solutol propofol showed no increase of triglyceride and the propofol concentrations showed no difference between the two groups. Also the original propofol supported the growth of all microorganisms at both temperatures and times. EDTA added propofol inhibited the growth of microorganisms more than the original propofol, but not as much as the poloxamer-solutol formulated propofol. Saline showed a similar pattern as the propofol with added EDTA. Conclusions: The poloxamer-solutol formulated propofol has advantages by pharmacokinetic-pharmacodynamic studies in terms of the initial TG level during propofol infusion, and shows more bacteriostatic activity against all four microorganisms than the original propofol and the propofol with added EDTA." @default.
• W2321172020 created "2016-06-24" @default.
• W2321172020 creator A5002026238 @default.
• W2321172020 creator A5009956881 @default.
• W2321172020 creator A5020291782 @default.
• W2321172020 creator A5044444976 @default.
• W2321172020 creator A5056145064 @default.
• W2321172020 creator A5082124715 @default.
• W2321172020 creator A5088724351 @default.
• W2321172020 date "2003-01-01" @default.
• W2321172020 modified "2023-09-27" @default.
• W2321172020 title "The Experimental Study Using Beagle Dogs for the Clinical Application of Poloxamer-solutol Propofol" @default.
• W2321172020 doi "https://doi.org/10.4097/kjae.2003.45.5.641" @default.
• W2321172020 hasPublicationYear "2003" @default.
• W2321172020 type Work @default.
• W2321172020 sameAs 2321172020 @default.
• W2321172020 citedByCount "0" @default.
• W2321172020 crossrefType "journal-article" @default.
• W2321172020 hasAuthorship W2321172020A5002026238 @default.
• W2321172020 hasAuthorship W2321172020A5009956881 @default.
• W2321172020 hasAuthorship W2321172020A5020291782 @default.
• W2321172020 hasAuthorship W2321172020A5044444976 @default.
• W2321172020 hasAuthorship W2321172020A5056145064 @default.
• W2321172020 hasAuthorship W2321172020A5082124715 @default.
• W2321172020 hasAuthorship W2321172020A5088724351 @default.
• W2321172020 hasBestOaLocation W23211720201 @default.
• W2321172020 hasConcept C101335993 @default.
• W2321172020 hasConcept C111113717 @default.
• W2321172020 hasConcept C112705442 @default.
• W2321172020 hasConcept C126322002 @default.
• W2321172020 hasConcept C15920480 @default.
• W2321172020 hasConcept C178790620 @default.
• W2321172020 hasConcept C185592680 @default.
• W2321172020 hasConcept C2776277131 @default.
• W2321172020 hasConcept C2776820430 @default.
• W2321172020 hasConcept C2780306666 @default.
• W2321172020 hasConcept C42219234 @default.
• W2321172020 hasConcept C521977710 @default.
• W2321172020 hasConcept C71924100 @default.
• W2321172020 hasConcept C98274493 @default.
• W2321172020 hasConceptScore W2321172020C101335993 @default.
• W2321172020 hasConceptScore W2321172020C111113717 @default.
• W2321172020 hasConceptScore W2321172020C112705442 @default.
• W2321172020 hasConceptScore W2321172020C126322002 @default.
• W2321172020 hasConceptScore W2321172020C15920480 @default.
• W2321172020 hasConceptScore W2321172020C178790620 @default.
• W2321172020 hasConceptScore W2321172020C185592680 @default.
• W2321172020 hasConceptScore W2321172020C2776277131 @default.
• W2321172020 hasConceptScore W2321172020C2776820430 @default.
• W2321172020 hasConceptScore W2321172020C2780306666 @default.
• W2321172020 hasConceptScore W2321172020C42219234 @default.
• W2321172020 hasConceptScore W2321172020C521977710 @default.
• W2321172020 hasConceptScore W2321172020C71924100 @default.
• W2321172020 hasConceptScore W2321172020C98274493 @default.
• W2321172020 hasIssue "5" @default.
• W2321172020 hasLocation W23211720201 @default.
• W2321172020 hasOpenAccess W2321172020 @default.
• W2321172020 hasPrimaryLocation W23211720201 @default.
• W2321172020 hasRelatedWork W1997190734 @default.
• W2321172020 hasRelatedWork W2113218652 @default.
• W2321172020 hasRelatedWork W2321172020 @default.
• W2321172020 hasRelatedWork W2358611292 @default.
• W2321172020 hasRelatedWork W2376033558 @default.
• W2321172020 hasRelatedWork W2592379712 @default.
• W2321172020 hasRelatedWork W2899084033 @default.
• W2321172020 hasRelatedWork W3008433136 @default.
• W2321172020 hasRelatedWork W3172339243 @default.
• W2321172020 hasRelatedWork W3209098127 @default.
• W2321172020 hasVolume "45" @default.
• W2321172020 isParatext "false" @default.
• W2321172020 isRetracted "false" @default.
• W2321172020 magId "2321172020" @default.
• W2321172020 workType "article" @default.